ClinicalTrials.gg
DrugRead study by study

Omalizumab clinical trials

Also written Xolair, IGE025 and CT-P39.

studies test it
168
open now
10
in phase 3
43
first study started
2000
ClinicalTrials.gov finds 260 studies for Omalizumab. How that becomes 168 hereChecked on ClinicalTrials.gov

Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives Omalizumab. Its counts are asked again every night. How drug pages count

  1. 260Found by its intervention search · See all 260 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 221 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −10
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 250Give Omalizumab to participants
  4. −47Observe patients on it, or give it outside a trial
  5. −2Use it as a tool: an imaging tracer or a test of drug response
  6. −26Compare another treatment with it
  7. −7Give it beside what is tested
  8. 168Test it: the count on this site

Get an email when these change. Save the Omalizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Jun 2003 · XOLAIR · BLA 103976 (FDA, Drugs@FDA)
European Union
25 Oct 2005 · Xolair · EMEA/H/C/000606 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Omalizumab
117
Omalizumab (Xolair)
12
Xolair (omalizumab)
6
Omalizumab Injection
4
Omalizimab
2

Brand

Xolair
78
Xolair 300 mg
1

Development codes

IGE025
6
CT-P39
2
ADL-018
2
RO5489789
2
GNR-044
1
RhuMab-E25
1
SYN008
1

Studies by the year they started

167 studies that test it; most in 2005 (12)

Studies that test Omalizumab, by start year
YearStudies
20001
20012
20023
20035
20049
200512
200612
200710
20084
200912
20106
20118
20127
20138
201412
20153
20162
20178
20184
20197
20207
20217
20226
20232
20244
20253
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
17
Phase 2
45
Phase 3
43
Phase 4
59
No phase
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 62 · Other 106

Novartis Pharmaceuticals (19) · Genentech, Inc. (16) · Novartis (12) · Johns Hopkins University (11) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Stanford University (4) · Hoffmann-La Roche (4) · Creighton University (4)

Often tested with

Tested in the same studies.

Dupilumab (3) · cow's milk (1) · Fluticasone (1) · Anti-IgE antibodies (1) · Itraconazole (1) · Mepolizumab (1) · Rituximab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Omalizumab is the comparator. A study of two new drugs counts under both.

  • 1Remibrutinib · Novartis Pharmaceuticals
  • 1LP-003 · Longbio Pharma · next primary completion Mar 2028
Reaching primary completion within a year · 4

Studies that test Omalizumab.

Studies

Open first, then newest update. How each study uses Omalizumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 168

See all 168 studies that test Omalizumab →

Behind its US label · 6 — the studies the FDA label of XOLAIR, OMLYCLO describes

From the Clinical Studies section of XOLAIR (2026-08), OMLYCLO (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 130 — no other medicine in its arm

Showing 20 of 130. See all 130 →

Tested with established drugs · 19 — they are given beside it
Tested in a combination · 19 — another drug in the study is under test too
Beside an established treatment under test · 3 — an approved drug, surgery or radiation is what the study tests

Tested with Omalizumab: peanut 1

Beside a new treatment under test · 2 — a new drug, cell therapy or vaccine is what the study tests
Beside supportive care · 1 — a supportive treatment or test is studied
One option of several · 1 — a test or a strategy chooses among drugs
As the comparator · 26 — what is tested is compared with Omalizumab

Showing 20 of 26. See all 26 →

Observed · 47 — patients on it are followed, or it is given outside a trial

Showing 20 of 47. See all 47 →

As a tool · 2 — an imaging tracer or a test of drug response

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call Omalizumab · ClinicalTrials.gg INT006578

  • MeSH (NLM) D000069444OmalizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 2P471X1Z11OMALIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 302379Confirmed FDA, Wikidata
  • Wikidata Q415392omalizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C29299OmalizumabOne source FDA
  • DrugBank DB00043One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion